At the news
? NEUTRALIMPACT 2/10 SC 13G/A filed Nov 13, 2026 at 17:08 ET
Capital Research Global Investors (CRGI) filed an amended Schedule 13G disclosing a 8.2% passive stake in Alnylam Pharmaceuticals as of September 30, 2026, down from 10.4% in the prior filing. The reduction reflects routine portfolio rebalancing by a large passive holder and does not signal any change in investment intent or control.
- CRGI disclosed beneficial ownership of 10,940,905 shares of Alnylam common stock as of September 30, 2026.
- The stake represents 8.2% of the 133,809,118 shares outstanding.
- This is a decrease from the prior filing where CRGI reported a 10.4% stake.
- The filing certifies passive intent with no plans to influence control.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access